2

Click here to load reader

Daily sgx sinagpore report by epic research singapore 31th july 2014

Embed Size (px)

DESCRIPTION

Epic Research private limited have best technical research team, Our research team provide Daily report on SGX Singapore and SGX Exchange, You can get Daily Favorable Tips & future Strategy for SGX Stocks Market.

Citation preview

Page 1: Daily sgx sinagpore report by epic research singapore 31th july 2014

DAILY REPORT 31th JULY

Y O U R M I N T V I S O R Y

Page 1

TOP GAINERS & LOSERS

TOP GAINER % Change

Oversea-Chinese Bank... +1.54%

CapitaLand Ltd +0.91%

United Overseas Bank... +0.29%

DBS Group Holdings L... +0.28%

Hongkong Land Holdin... +0.15%

Singapore Airlines L... 0.00%

Singapore Telecommun... 0.00%

Genting Singapore PL... 0.00%

StarHub Ltd -0.24%

Jardine Matheson Hol... -0.53%

TOP LOSER % Change

SIA Engineering Co L... -1.88%

CapitaMall Trust -1.49%

Jardine Strategic Ho... -1.16%

Noble Group Ltd -1.05%

Singapore Exchange L... -0.98%

Ascendas Real Estate... -0.85%

Olam International L... -0.79%

ComfortDelGro Corp L... -0.78%

City Developments Lt... -0.57%

Hutchison Port Holdi... 0.00%

Singapore Airlines L... -1.98%

Olam International L... -1.23%

ComfortDelGro Corp L... -1.21%

Singapore Press Hold... -0.94%

Straits Times Index (STI)

OCBC CAPL UOB DBS HKLD SIA STE GSP STH JM

% Change 1.54% 0.91% 0.29% 0.28% 0.15% 0.00% 0.00% 0.00% -0.24 -0.53

-1.00%

-0.50%

0.00%

0.50%

1.00%

1.50%

2.00%TOP GAINERS

SIA CM JSNOBAL

SGXASREI

TOLAM

CD CID HPHT

%Change -1.88 -1.49 -1.16 -1.05 -0.98 -0.85 -0.79 -0.78 -0.57 0.00%

-2.00%

-1.80%

-1.60%

-1.40%

-1.20%

-1.00%

-0.80%

-0.60%

-0.40%

-0.20%

0.00%

TOP LOOSERS

Snapshot for Straits Times Index STI (FSSTI)

Open 3,356.07

Previous Close 3,356.08

Day Range 3,349.68 – 3,364.05

Year-to- Date +7.61%

1-Year +6.47%

52-Week Range 2953.01-3364.05

Page 2: Daily sgx sinagpore report by epic research singapore 31th july 2014

DAILY REPORT 31th JULY

Y O U R M I N T V I S O R Y

Page 2

Disclaimer

The information and views in this report, our website & all the service we provide are believed to be reliable, but we do not accept any responsibility (or liability) for errors

of fact or opinion. Users have the right to choose the product/s that suits them the most.

Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider

reliable.

This material is for personal information and based upon it & takes no responsibility

The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice.

Epic research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser.

Epic research shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of NSE and

BSE.

The share price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change

without notice. Analyst or any person related to epic research might be holding positions in the stocks recommended. It is understood that anyone who is browsing through

the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible

for . Any surfing and reading of the information is the acceptance of this disclaimer. All Rights Reserved.

Investment in equity & bullion market has its own risks.

We, however, do not vouch for the accuracy or the completeness thereof. We are not responsible for any loss incurred whatsoever for any financial profits or loss which

may arise from the recommendations above epic research does not purport to be an invitation or an offer to buy or sell any financial instrument. Our

Clients (Paid or Unpaid), any third party or anyone else have no rights to forward or share our calls or SMS or Report or Any Information Provided by us to/with anyone

which is received directly or indirectly by them. If found so then Serious Legal Actions can be taken.

Give us a missed call at +6531581402 Visit us @ www.epicresearch.sg

RESEARCHERS from the Singapore General Hospital and the

Duke-NUS Graduate Medical School are a step closer to finding

a treatment for dengue fever, which currently cannot be

treated with an antiviral drug or vaccinated against. The

progress comes after the researchers found that Celgosivir, a

medicine derived from the seeds of the Moreton Bay Chestnut

trees, to be safe for dengue patients.

STEPHEN Lee is stepping down as President of the Singapore

National Employers Federation (SNEF) on August 31, after 26

years at the helm. He will be succeeded by Robert Yap, the

current chairman and chief executive of home-grown logistics

company YCH Group, on Sep 1. Dr Yap is one of four vice-

presidents at SNEF.

TATA Consultancy Services (TCS) announced on Wednesday

that it is the official IT consultancy partner of the Standard

Chartered Singapore Marathon (SCMS) 2014. It will provide a

mobile application and technology support for the event. Vish

Iyer, President,

THE Building and Construction Authority (BCA) has granted

S$8.3 million to researchers from the National University of

Singapore (NUS), Nanyang Technological University and Ngee

Ann Polytechnic to develop energy efficient technologies.

DBS GROUP HOLDING

BUY DBS GROUP HOLDING ABOVE 18.090 TG 18.190,

18.300, 18.440 SL 17.950

MARKET UPDATES & STOCK RECOMMENDATION